Syra Health Corp

Syra Health Corp. announced its Annual Meeting of Stockholders to be held on July 23, 2026, where shareholders will vote on several key proposals. These include the election of five directors, the ratification of M&K CPAS, PLLC as the independent auditor for fiscal year 2026, and an amendment to the 2022 Omnibus Equity Incentive Plan to increase Class A shares available for issuance to 4,100,000. The record date for voting eligibility was set for May 28, 2026.

Syra Health Corp. reported a significant turnaround in Q1 2026, achieving a net income of $240,979 compared to a net loss of $472,265 in Q1 2025. Net revenues increased by 22.4% to $2.27 million, driven by strong growth in Population Health services. The company also saw a substantial increase in cash from operating activities and deferred revenue, though it continues to acknowledge substantial doubt about its ability to continue as a going concern.

Syra Health Corp. reported its first-ever profitable quarter in Q1 2026, with net income of approximately $241,000, a significant improvement from a net loss of $(472,265) in the prior year. Total revenue increased by 22% to $2.3 million, driven by strong growth in population health solutions. The company also expanded its gross margin to 42.7% and ended the quarter with $2.9 million in cash and no long-term debt. Operational highlights include key contract renewals and industry awards for its innovative health solutions.

Syra Health Corp filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K to include previously omitted information regarding corporate governance, executive compensation, and related party transactions. The filing details significant management changes, including the appointment of Gregory R. Alexander as CEO effective January 5, 2026, following the termination of former CEO Deepika Vuppalanchi for cause and the passing of former President Sandeep Allam. The amendment also outlines compensation for the new CEO and other executives, director compensation, and various related party transactions.

Syra Health Corp. filed an Amendment No. 1 to its Annual Report on Form 10-K for fiscal year 2025 to include previously omitted information regarding directors, executive compensation, security ownership, related party transactions, and principal accountant fees. The amendment details the appointment of Gregory R. Alexander as CEO, the termination of former CEO Deepika Vuppalanchi, and the passing of former President Sandeep Allam. It also outlines compensation for executives and directors, and discloses related party transactions.